Twist Bioscience : June 2024 Corporate Deck

J U N E 2 0 2 4

Writing the Future

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Legal Disclaimers

This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, annual financial guidance for fiscal 2024, statements regarding Twist Bioscience's path to profitability, future growth, expansion, market share gains and Twist Bioscience's other expectations regarding its future operations plans and financial performance, timing of end to end workflow for DNA data storage, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties relating to COVID-19; the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience's patents or proprietary rights; and the risk that Twist Bioscience's proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in Twist Bioscience's Annual Report on Form 10-K filed with the SEC on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

2

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Scalable, Profitable Growth

Defined path to profitability

New products, growth for margin expansion

Consistent operational excellence

Strong commercial execution in growing markets Continued revenue and market share growth

Twist Today

3

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

PROTEINS

DNA

RNA

	One chip
	Unprecedented scale,
	many opportunities for
	cost efficient expansion
MORE	MORE
Products	Customers
MORE	MORE
Applications	Markets

DNA on Silicon Platform

4

Interconnected Product Groups Leverage the Same Chip

NGS	Panels	RNA	Library
for target
READ	Seq	Prep
enrichment

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

DNA

on Silicon

Platform

SYN BIO	Synthesize
WRITE	oligonucleotides
	Variant Libraries

BIOPHARMA	Library of
SOLUTIONS	Libraries

Assemble

gene fragments

Assemble

clonal genes

Express into lgG proteins

5

A Differentiated

• Low variable costs enable rapid margins ramp

and Innovative Compelling BUSINESS MODEL • High fixed costs deter new entrants into market

Business

Exceptional USER EXPERIENCE

• Integrated eCommerce platform

• Fast and easy ordering, high NPS

and CONFIDENTIAL

Scalable INFRASTRUCTURE

• Delivering >280,000 genes per month + RNA, Protein

• Expanding through additional products

BIOSCIENCE | PROPRIETARY

Powerful PRODUCTION

• 16 million+ oligo/day capacity

• Up to 10,000x greater scale and throughput than 96 well plate-based approach

| TWIST

Proven Silicon PLATFORM

• 10+ years of development, increasingly complementary product lines

• Proprietary DNA writer, software

6

Strong Annual Revenue Growth and Gross Margin

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

						$203.6M
						41%
						GM
					$132.3M
				$90.1M	39%
					GM
			$54.4M	32%
		$25.4M	13%	GM
	$10.8M
$2.3M		GM
FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022

$245.1M

37%

GM

2nd Manufacturing site added

in 2023

FY 2023

7

Strong Quarterly Revenue Growth

$ in Millions

$75.3

$71.5

$66.9

Biopharma	$63.7
NGS	$60.2
	$57.3
SynBio	$56.1
$54.2
	$48.1

CONFIDENTIAL

$32.4

$42.0

$38.0

$35.0

$31.2

TWIST BIOSCIENCE| PROPRIETARY and

$6.5

$28.2

$21.2

$17.2 $19.3

$15.7

$13.6 $13.6

$11.5

$8.4

|

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

Jun

Sep

Dec

Ma r

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

8

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Clear Path to Profitability Across Product Groups

Life Sciences Tools

Applied Markets

SYN BIO	NGS	BIOPHARMA	DNA DATA
1 WRITE	2 READ	3 SOLUTIONS	4 STORAGE

9

1

| TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL

Life Sciences Tools

SYN BIO WRITE

Large End Markets		Diverse Applications
Pharma	Agriculture	•	Target discovery and validation
		•	Antigen production
Biotech	Academic labs	•	Antibody discovery, screening and production
		• Enzyme, protein, and cellular engineering
Industrial chemicals		•	Protein expression
	•	CRISPR applications

Innovative Products

Clonal genes	Oligo pools	Variant	IgG proteins
Express genes		Libraries
Gene fragments

10

DNA on Silicon Platform